Abstract
Denosumab is a monoclonal antibody which binds to the receptor activator of nuclear factor- κB ligand (RANKL), reducing osteoclastic activity and bone turnover. The Fracture REduction Evaulation of Denosumab in Osteoporosis every 6 Months (FREEDOM) trial showed a significant reduction in relative risk of fractures with increased bone mineral density (BMD) with denosumab. A trial of DenosumAb versus placebo in Males with Osteoporosis (ADAMO) demonstrated the similar effect of denosumab for improving BMD and reducing bone turnover in men. However, concerns were identified regarding increased risk of fractures with denosumab cessation. Until further evidence is available, bisphosphonate treatment is recommended to attenuate this risk with denosumab discontinuation. Keywords: Denosumab, fracture, osteoporosis
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
